LSE - Delayed Quote EUR

Biocartis Group NV (0R72.L)

1.7340

+0.0143

(+0.83%)

At close: July 21 at 5:40 PM GMT+1

Key Events

Loading Chart for 0R72.L

9/21 12:03 PM

DELL

Previous Close 1.7197
Open 1.7197
Bid --
Ask --
Day's Range 1.7200 - 1.7200
52 Week Range 0.2865 - 1.7200
Volume --
Avg. Volume 74,375
Market Cap (intraday) --
Beta (5Y Monthly) 1.29
PE Ratio (TTM) --
EPS (TTM) --
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

www.biocartisgroupnv.be

526

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)

Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion

Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion

Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting

Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting

Press release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors

Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO)

Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO)

Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio

Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio

Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit

Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit

Press Release Biocartis Group NV: Disclosure of transparency notification

Press Release Biocartis Group NV: Disclosure of transparency notification

Press Release Biocartis Group NV: Biocartis announces H1 2023 Results and provides an update on the operational reorganization and recapitalization

Press Release Biocartis Group NV: Biocartis announces H1 2023 Results and provides an update on the operational reorganization and recapitalization

Press Release Biocartis Group NV: Agreement regarding recapitalization of operating subsidiaries by secured by secured creditors and wind down of listed holding company

Press Release Biocartis Group NV: Agreement regarding recapitalization of operating subsidiaries by secured by secured creditors and wind down of listed holding company

Press release Biocartis Group NV: Biocartis 2023 half-year results webcast on 26 September 2023

Press release Biocartis Group NV: Biocartis 2023 half-year results webcast on 26 September 2023

Trailing total returns as of 4/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

0R72.L

0.00%

MSCI WORLD

5.23%

1-Year Return

0R72.L

186.61%

MSCI WORLD

18.44%

3-Year Return

0R72.L

61.92%

MSCI WORLD

12.98%

5-Year Return

0R72.L

85.53%

MSCI WORLD

53.42%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Biocartis Group NV

1.7340

+0.83%

Mkt Cap EUR -

Industry -

Valuation Measures

As of

Market Cap

--
Enterprise Value

--
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

--
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

-111.58%
Return on Assets (ttm)

-24.03%
Return on Equity (ttm)

--
Revenue (ttm)

60.82M
Net Income Avi to Common (ttm)

-67.87M
Diluted EPS (ttm)

--

Balance Sheet and Cash Flow

Total Cash (mrq)

25.18M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

-36.09M

0R72.L does not have Company Insights